A study by Biofourmis aims to improve patient centricity in the drug approval processes by using wearable technology and mobile software to monitor the quality of life for patients with heart failure.
Insilico Medicine develops a semi-automated contracting system to ease the collaboration process between AI companies and industry partners in the discovery space.
MIT has developed an ‘invisible’ device that provides several benefits over traditional patient data collection methods, including improved biomarker development and the ability to detect changes in behavior – by monitoring patients wirelessly, and through...
A collaboration between Mercachem and Gotham leads to the generation of a molecule library, expected to enable new discovery opportunities in the epitranscriptomic targets space.
Lovelace’s support and the inclusion in a $20m NIH contract enable Exemplar to continue the development of a porcine animal model for Sickle Cell Disease research.
Eversana adopts Cryoport’s full suite of logistics services, in an alliance expected to ‘drive synergistic growth’ for both companies and answer regenerative medicine demands.
Sponsors to benefit from more accurate, shorter, and less costly trials through Shimmer Research and ClearSky Medical Diagnostics partnerships, says company executive.
Clinical trials are taking longer, drug development costing more, and the stakeholder group expanding – all compounding to create an "industrywide urgency to streamline how trials are run,” says Veeva VP.
Transforming statistical data into a surrogate endpoint can enable comprehension of trial results sooner than usual, but few make the cut after formal validation, says drug development expert and DIA panelist.
In which areas is artificial intelligence most mature? What are the challenges to widespread adoption? Tufts and DIA recently teamed up to explore these questions.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
As regulators work to advance the modern clinical trial, the risk-averse clinical research industry is falling behind in the race to bring new therapies to patients, says an industry expert, echoing the former FDA commissioner’s calls for innovation.
